Chronic Rhinosinusitis Optimisation of Nasal Outcomes and Scores (CHRONOS): An Italian Delphi Consensus on Long-Term Management with Biologics.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
De Corso Eugenio, Canevari Frank Rikki Mauritz, Caminati Marco, Pipolo Carlotta, Heffler Enrico, Lazzeroni Matteo, Seccia Veronica, Garzaro Massimiliano, Ottaviano Giancarlo, Cantone Elena, Pagella Fabio, Gramellini Giulia, La Mantia Ignazio, Gallo Stefania, Moffa Antonio, Pasquini Ernesto, Loperfido Antonella, Torretta Sara, Cecchi Lorenzo, Fadda Gian Luca, Maggiore Giandomenico, Pelucchi Stefano, Iannuzzi Lucia, Lucidi Daniela, Macchi Alberto, Padoan Roberto, Patella Vincenzo, Dané Giulia, Schroeder Jan, Montuori Claudio, Corbò Marco, Canonica Giorgio Walter, Senna Gianenrico
Аннотация
RECENT FINDINGS: Accumulating real-world and clinical trial data confirm the sustained efficacy and safety of biologics targeting type 2 inflammation, enabling durable control and remission in a significant proportion of patients. Personalized dosing regimens, including dose-spacing strategies, appear feasible. The CHRONOS project provides practical guidance for optimizing long-term biologic therapy in severe CRSwNP. Response assessment should combine subjective and objective measures, especially for olfactory testing. Biologics may be considered before surgery only in selected complex cases. Dose-spacing strategies may be appropriate in stable patients but require multidisciplinary oversight in those with comorbid asthma. Adverse events are uncommon. The concept of disease modification is endorsed, recognizing biologics' potential to alter the natural history of CRSwNP.